SYS-CON MEDIA Authors: Bob Gourley, Greg Schulz, Don Nelson, Gilad Parann-Nissany, Noel Wurst

News Feed Item

Global RNA Interference (RNAi) Therapy Market Outlook 2018

DUBLIN, April 1, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/5wxkx8/global_rna) has announced the addition of the "Global RNA Interference (RNAi) Therapy Market Outlook 2018" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry. 

Since discovery, RNA interference is considered to be a turning point for molecular biology, it is most likely that this technology would grow in terms of its popularity and the significant research activity would be recorded in order to develop efficient and safe drug delivery mechanisms based on the RNAi therapy. Being a powerful tool for the study of functional genomics, this therapy provides enables the scientist to successfully silence any gene with artificial triggers of RNAi and utilizing the cellular machinery for efficient targeting of complementary transcripts. 

There are specific strategic reasons for the pharmaceutical industry to take interest in developing RNAi-based therapeutics. With the existing product pipelines exhausting for the big pharma companies, they are currently looking into RNAi therapeutics as potential fields which would enable the pipelines to be filled. 

Additionally, these companies have identified RNAi therapeutics to have the capability to target those diseases which are considered to be undruggable by small-molecule compounds or biologics. Thus, by investing in RNAi therapeutics at an early stage, the pharma companies would be able to build a strong foothold and have a commanding position in the market once these RNAi-based drugs reached the market.

The RNAi therapy market, in the future years is likely to witness an increased level of activity in terms of RNAI technology development, specifically in the space of drug delivery. Though the main concept and clinical results behind RNAi are compelling, the pharma companies are still working towards identifying some new ideas which have great opportunity to grow. 

Key Topics Covered: 

1. Introduction to RNA Interference (RNAi) Therapy
2. Benefits of RNA Interference (RNAi) Therapy
3. RNA Interference (RNAi) Drug Delivery Mechanics
4. Global RNA Interference (RNAi) Therapy Market Overview
5. Global RNA Interference (RNAi) Market Dynamics
6. RNAi Clinical Pipeline by Phase, Indication & Country
7. Suspended & Discontinued RNAi Profiles
8. Competitive Landscape

Companies Mentioned:

  • Arrowhead Research
  • Alnylam Pharmaceuticals
  • Benitec Biopharma
  • Dicerna Pharmaceuticals
  • InteRNA Technologies
  • Isis Pharmaceuticals
  • RXi Pharmaceuticals
  • Santaris Pharma
  • Silence Therapeutics
  • Tekmira Pharmaceuticals Corporation

For more information visit http://www.researchandmarkets.com/research/5wxkx8/global_rna

Media Contact: Laura Wood, +353-1-481-1716, [email protected]

SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.